PODD · INSULET CORP · Top AI ETF

Back to holdings

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.

Close · 3M

-34.20%

Held by 0 AI ETFs

None of the tracked AI ETFs currently hold this name.

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals4

Win rate75% (3/4)

Avg buy return-0.18%

AIEQno longer held6 signals

AIEQ · Exit · 1d

Amplify ETFs' AIEQ, leveraging IBM Watson NLP for daily stock rankings, swiftly rebalances its 140-180 US stock portfolio in response to shifting market signals. Despite PODD’s 31.93% revenue growth, the fund likely detected a negative change in sentiment or fundamental outlook that outweighed its recent positive 30-day price movement. This is suggested by Insulet Corp's significant longer-term price depreciation, recording a -47.1% 1-year return and trading at only 45% of its 52-week high. The daily ranking system, integrating both fundamentals and sentiment, led to a re-evaluation, resulting in PODD's complete removal from the portfolio on 2026-07-01, indicating a rapid response to a perceived decline in its investment thesis.

weight 0.300% → 0 (exited)·stock up 7.9% in the 30 days before

Jul 1·entry $159.79·now $159.12

-0.42%

since Jul 1

AIEQ · Weight increase · 3d

Trading at $158.25, which is just 45% of its 52-week high of $352.82 and still down 48.1% over the past year, Insulet Corp (PODD) has recently seen a 30-day return of 6.4% after a 38.7% drop over 90 days. Within this context of a potential rebound from deep lows, AIEQ's daily rebalancing mechanism, driven by IBM Watson NLP analyzing news, filings, and even social posts, registered consecutive weight increases for PODD from 0.28% to 0.31% between June 25th and June 28th. This suggests Watson's analysis identified a strengthening positive outlook or an improved daily ranking for the company, potentially discerning favorable sentiment or future catalysts from its ingested unstructured data, even as the stock carries a P/E of 32.91 and P/B of 13.2. The fund's broad market, fundamentals plus sentiment hybrid style likely found a compelling reason to incrementally add to a company exhibiting 31.93% revenue growth and 17.37% ROE, despite its significant past decline.

weight 0.280% → 0.310% (+0.030 pp)·stock up 8.4% in the 30 days before

Jun 28·entry $157.74·now $159.12Fresh

+0.87%

since Jun 28

AIEQ · Weight increase · 2d

PODD's 31.93% Revenue Growth and 17.37% Return on Equity (ROE) represent fundamental strengths that EquBot's AI, managing AIEQ, considers in its broad market, fundamentals + sentiment hybrid strategy. Despite a PER of 32.91 and PBR of 13.2, these figures point to a business with strong underlying financial performance. This sequential increase in AIEQ's allocation to PODD, starting on 2026-06-25, coincides with the stock trading at 45% of its 52-week high, following significant long-term declines but showing a recent 30-day positive return of +6.4%. IBM Watson NLP, analyzing thousands of data points daily, likely detected a shift in sentiment for PODD around these lower price levels, suggesting a potential turning point. The sustained weighting increase from 0.2800% to 0.3000% by 2026-06-26 reflects EquBot's daily ranking and risk overlay validating this combination of fundamental appeal and positive sentiment at a discounted price.

weight 0.280% → 0.300% (+0.020 pp)·stock up 8.4% in the 30 days before

Jun 26·entry $158.25·now $159.12Fresh

+0.55%

since Jun 26

AIEQ · Weight decrease · 2d

The consecutive weight decrease from 0.31% to 0.29% for Insulet Corp, executed as two daily, 0.01% decrements, represents a measured adjustment rather than an abrupt exit from the position. This gradual reduction aligns with AIEQ's daily rebalancing and high-turnover approach, where its IBM Watson NLP engine likely registered a persistent, albeit minor, deterioration in sentiment or a modest decline in PODD's daily rank. Given Insulet Corp's current trading at $149.70, near its 52-week low and experiencing a 30-day return of -14.5%, such a gradual move suggests that while market sentiment remains weak, its underlying revenue growth of 31.93% and ROE of 17.37% prevent a more drastic portfolio adjustment. The fund’s hybrid strategy, considering both fundamentals and sentiment, would interpret the sustained price weakness alongside a high PER of 33.92 as a continued signal to trim exposure incrementally without entirely divesting from a company still showing considerable top-line expansion.

weight 0.310% → 0.290% (-0.020 pp)·stock up 0.6% in the 30 days before

Jun 12·entry $149.70·now $159.12

+6.29%

since Jun 12

AIEQ · Weight increase · 2d

weight 0.270% → 0.300% (+0.030 pp)·stock up 1.3% in the 30 days before

Jun 7·entry $151.51·now $159.12Drifting

+5.02%

since Jun 7

AIEQ · New entry · 1d

The AI ETF likely re-entered PODD due to its exceptional 30.73% revenue growth and strong 17.37% ROE, indicating a focus on robust fundamental performance and growth potential in the healthcare sector, even with elevated valuation multiples. This illustrates that AI funds may prioritize strong growth over traditional valuation metrics; retail investors should understand the increased volatility risks associated with such high-growth investments before making similar decisions.

weight 0 → 0.050% (new)·stock down 15.5% in the 30 days before

May 3·entry $171.39·now $159.12Fresh

-7.16%

since May 3

PQUSno longer held3 signals

PQUS · Exit · 1d

PODD, trading at $149.19 on June 12, 2026, sat near the lower end of its $142.43 to $352.82 52-week range, having experienced a -40.6% return over 90 days and a -54.1% decline across the past year. This significant price depreciation likely triggered a re-evaluation within Pictet Asset Management's AI ranking system, leading to PODD's removal from PQUS's approximately 165 US large-cap holdings on June 12, following a period where its weight had gradually increased from 0.16% to 0.18%. While PODD demonstrated a 31.93% revenue growth and 17.37% return on equity, its PER of 33.92 and PBR of 13.2, set against the backdrop of such price volatility, may have caused the AI to de-rank it below the threshold for inclusion given the fund's sector-balance and concentration rules. The AI-managed fund, with its measured turnover, acted on a periodic rebalance cycle to remove a stock whose recent market performance likely outweighed its fundamental metrics in the AI's current ranking.

weight 0.180% → 0 (exited)·stock up 0.6% in the 30 days before

Jun 12·entry $149.70·now $159.12

+6.29%

since Jun 12

PQUS · Weight decrease · 3d

The AI-managed ETF is likely de-risking from PODD due to its extremely high valuation metrics, such as the PER and PBR, despite its impressive revenue growth and ROE. This suggests the algorithm perceives the stock as overvalued and is reducing exposure to manage potential downside risk. For retail investors, this serves as a practical reminder to balance a company's strong fundamentals and growth with its current market valuation, potentially signaling a good time to reassess high-priced positions or consider partial profit-taking.

weight 0.180% → 0.140% (-0.040 pp)·stock down 18.0% in the 30 days before

Apr 30·entry $172.14·now $159.12

-7.56%

since Apr 30

PQUS · Weight decrease · 2d

The AI ETF is likely decreasing its weight in PODD due to its extremely high valuation (PER 49.86, PBR 13.2), suggesting a strategic move to de-risk from potentially overextended assets despite strong current revenue growth and ROE. This implies the AI prioritizes valuation risk management. For retail investors, this pattern indicates a need to critically evaluate if PODD's current price is sustainable given its high valuation, even with robust fundamentals, and to consider the potential for valuation-driven corrections.

weight 0.180% → 0.160% (-0.020 pp)·stock down 23.1% in the 30 days before

Apr 29·entry $160.02·now $159.12

-0.56%

since Apr 29

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of Jun 28

The AI ETF AIEQ is showing a weight increase trend for Insulet Corp, indicating a positive view and accumulation of shares. This action directly contrasts with the framework's 'Fail' verdict, which is primarily driven by a lack of complete financial health data and the absence of a clear margin of safety at the current valuation.

Circle of CompetenceThe company's focus on a recurring-revenue medical device for a chronic condition offers reasonable predictability for unit economics and long-term cash flows, despite industry innovation.
Economic MoatThe company benefits from switching costs for patients and healthcare providers, a recognized brand in a critical medical device niche, and intellectual property protection and regulatory hurdles for new entrants.
ManagementInsufficient information is available to assess management's candor, capital allocation discipline, or extent of skin in the game.
Financial HealthThe provided financials are insufficient to assess a 10-year average ROE, operating margin stability, debt manageability, or owner earnings, preventing a conclusive evaluation of financial health against the framework's criteria.
Margin of SafetyThe current valuation metrics, including a PER of 32.91 and PBR of 13.2, do not suggest a clear defensible discount to intrinsic value, making a sufficient margin of safety unlikely.

While Insulet Corp appears to operate within a predictable circle of competence and possesses a durable economic moat, a full assessment of its financial health and management practices is hindered by insufficient data. Crucially, the current valuation, marked by high multiples, does not present a discernible margin of safety under this investment framework.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.